Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes: An analysis of data from the Diabetes Control and Complications Trial

Diabetic Medicine

Volumn 30, Issue 1, 2013, Pages 95-99

  Maple Brown, L J ^a,b,c   Ye, C ^a   Retnakaran, R ^a,d  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c ROYAL DARWIN HOSPITAL   (Australia)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTION; AREA UNDER THE CURVE; BLOOD; COMPARATIVE STUDY; DIABETIC ANGIOPATHY; METABOLISM; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE;

AREA UNDER CURVE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MICROVESSELS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES;

EID: 84871084322     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12004     Document Type: Article

References (7)

1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008; 57: 995-1001.
3. DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44: 968-983.
4. DCCT Research Group. The Diabetes Control and Complications Trial (DCCT): Design and methodologic considerations for the feasibility phase. Diabetes 1986; 35: 530-545.
5. DCCT Research Group. Diabetes Control and Complications Trial (DCCT). Update. Diabetes Care 1990; 13: 427-433.
6. Orchard TJ, Forrest KY, Ellis D, Becker DJ. Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glycemic threshold revisited. Arch Intern Med 1997; 157: 1851-18560.
7. Hirsch IB, Brownlee M. Beyond hemoglobin A1c-need for additional markers of risk for diabetic microvascular complications. J Am Med Assoc 2010; 303: 2291-2292.